Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders: Findings From the Suffolk County Mental Health Project.
Journal
JAMA psychiatry
ISSN: 2168-6238
Titre abrégé: JAMA Psychiatry
Pays: United States
ID NLM: 101589550
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
pubmed:
12
12
2019
medline:
4
2
2021
entrez:
12
12
2019
Statut:
ppublish
Résumé
It remains uncertain whether people with psychotic disorders experience progressive cognitive decline or normal cognitive aging after first hospitalization. This information is essential for prognostication in clinical settings, deployment of cognitive remediation, and public health policy. To examine long-term cognitive changes in individuals with psychotic disorders and to compare age-related differences in cognitive performance between people with psychotic disorders and matched control individuals (ie, individuals who had never had psychotic disorders). The Suffolk County Mental Health Project is an inception cohort study of first-admission patients with psychosis. Cognitive functioning was assessed 2 and 20 years later. Patients were recruited from the 12 inpatient facilities of Suffolk County, New York. At year 20, the control group was recruited by random digit dialing and matched to the clinical cohort on zip code and demographics. Data were collected between September 1991 and July 2015. Analysis began January 2016. Change in cognitive functioning in 6 domains: verbal knowledge (Wechsler Adult Intelligence Scale-Revised vocabulary test), verbal declarative memory (Verbal Paired Associates test I and II), visual declarative memory (Visual Reproduction test I and II), attention and processing speed (Symbol Digit Modalities Test-written and oral; Trail Making Test [TMT]-A), abstraction-executive function (Trenerry Stroop Color Word Test; TMT-B), and verbal fluency (Controlled Oral Word Association Test). A total of 705 participants were included in the analyses (mean [SD] age at year 20, 49.4 [10.1] years): 445 individuals (63.1%) had psychotic disorders (211 with schizophrenia spectrum [138 (65%) male]; 164 with affective psychoses [76 (46%) male]; 70 with other psychoses [43 (61%) male]); and 260 individuals (36.9%) in the control group (50.5 [9.0] years; 134 [51.5%] male). Cognition in individuals with a psychotic disorder declined on all but 2 tests (average decline: d = 0.31; range, 0.17-0.54; all P < .001). Cognitive declines were associated with worsening vocational functioning (Visual Reproduction test II: r = 0.20; Symbol Digit Modalities Test-written: r = 0.25; Stroop: r = 0.24; P < .009) and worsening negative symptoms (avolition: Symbol Digit Modalities Test-written: r = -0.24; TMT-A: r = -0.21; Stroop: r = -0.21; all P < .009; inexpressivity: Stroop: r = -0.22; P < .009). Compared with control individuals, people with psychotic disrders showed age-dependent deficits in verbal knowledge, fluency, and abstraction-executive function (vocabulary: β = -0.32; Controlled Oral Word Association Test: β = -0.32; TMT-B: β = 0.23; all P < .05), with the largest gap among participants 50 years or older. In individuals with psychotic disorders, most cognitive functions declined over 2 decades after first hospitalization. Observed declines were clinically significant. Some declines were larger than expected due to normal aging, suggesting that cognitive aging in some domains may be accelerated in this population. If confirmed, these findings would highlight cognition as an important target for research and treatment during later phases of psychotic illness.
Identifiants
pubmed: 31825511
pii: 2757019
doi: 10.1001/jamapsychiatry.2019.3993
pmc: PMC6990826
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
387-396Subventions
Organisme : NIMH NIH HHS
ID : R01 MH110434
Pays : United States
Références
J Clin Psychiatry. 2014;75 Suppl 2:34-8
pubmed: 24919170
Schizophr Bull. 2014 Jul;40(4):744-55
pubmed: 23770934
Schizophr Res. 2005 Oct 1;78(1):27-34
pubmed: 15964177
Schizophr Bull. 2016 Jan;42(1):87-95
pubmed: 26101305
Am J Psychiatry. 2011 Nov;168(11):1186-94
pubmed: 21676994
Arch Gen Psychiatry. 2001 Jan;58(1):24-32
pubmed: 11146755
Arch Clin Neuropsychol. 2001 Jan;16(1):75-91
pubmed: 14590193
Schizophr Bull. 2018 Jan 13;44(1):158-167
pubmed: 28338779
Schizophr Bull. 2011 May;37(3):451-5
pubmed: 21505111
J Affect Disord. 2002 Dec;72(3):209-26
pubmed: 12450638
Schizophr Res. 2004 Dec 15;72(1):41-51
pubmed: 15531406
Neuropsychology. 1998 Jul;12(3):426-45
pubmed: 9673998
Am J Psychiatry. 2017 Nov 1;174(11):1075-1085
pubmed: 27978770
Schizophr Bull. 1992;18(2):243-55
pubmed: 1621071
Schizophr Bull. 2009 Sep;35(5):1022-9
pubmed: 18495643
Schizophr Bull. 2014 Nov;40(6):1319-27
pubmed: 24583905
J Abnorm Psychol. 2016 Nov;125(8):1103-1119
pubmed: 27819471
Schizophr Bull. 2014 Jan;40(1):143-51
pubmed: 23277615
J Int Neuropsychol Soc. 2018 Sep;24(8):805-820
pubmed: 30019663
Am J Psychiatry. 2004 Jun;161(6):996-1003
pubmed: 15169687
Schizophr Res. 2008 Oct;105(1-3):105-13
pubmed: 18657398
Psychol Med. 2019 Nov;49(15):2573-2581
pubmed: 30674361
Psychol Aging. 2005 Mar;20(1):3-18
pubmed: 15769210
Schizophr Bull. 2000;26(1):119-36
pubmed: 10755673
Psychol Med. 2011 Feb;41(2):225-41
pubmed: 20836900
Schizophr Res. 2009 Sep;113(2-3):189-99
pubmed: 19628375
Schizophr Res. 2005 Dec 15;80(2-3):137-49
pubmed: 16183257
Psychol Med. 2018 Feb;48(3):392-403
pubmed: 28735586
Schizophr Res. 2003 Feb 1;59(2-3):137-46
pubmed: 12414070
Schizophr Bull. 2006 Oct;32(4):666-78
pubmed: 16829550
Eur Neuropsychopharmacol. 2015 Feb;25(2):158-68
pubmed: 25261263
Am Psychol. 1994 Apr;49(4):304-13
pubmed: 8203802
Aust N Z J Psychiatry. 2011 Feb;45(2):93-108
pubmed: 21320033
Am J Psychiatry. 2010 Feb;167(2):160-9
pubmed: 20048021
Schizophr Bull. 2018 Feb 15;44(2):398-408
pubmed: 29462455
Schizophr Bull. 2011 Jul;37(4):768-77
pubmed: 19934212
Schizophr Bull. 2010 Mar;36(2):359-69
pubmed: 18644851
Am J Psychiatry. 2013 Nov;170(11):1275-84
pubmed: 23771174
Neurosci Biobehav Rev. 2011 Jan;35(3):573-88
pubmed: 20620163
Schizophr Res. 2016 Aug;175(1-3):57-63
pubmed: 27050475
Am J Psychiatry. 2008 Aug;165(8):978-87
pubmed: 18450928
J Affect Disord. 2015 Mar 15;174:580-8
pubmed: 25560194
Schizophr Res Cogn. 2014 Mar 1;1(1):e47-e52
pubmed: 25045625
Front Hum Neurosci. 2013 Oct 07;7:643
pubmed: 24109449
Eur Rev Aging Phys Act. 2016 Jan 21;13:1
pubmed: 26865880
Neuroepidemiology. 2017;49(3-4):121-128
pubmed: 29145205
Bipolar Disord. 2015 Aug;17(5):543-8
pubmed: 25846854
Schizophr Res. 2003 Dec 15;65(2-3):75-86
pubmed: 14630300
J Clin Psychiatry. 2008 May;69(5):712-9
pubmed: 18435565
Neuropsychology. 2014 Jul;28(4):653-65
pubmed: 24635711
J Nerv Ment Dis. 2001 Jan;189(1):49-55
pubmed: 11206665
J Affect Disord. 2006 Jul;93(1-3):185-92
pubmed: 16678909
Schizophr Res. 2013 May;146(1-3):201-8
pubmed: 23490758
Am J Psychiatry. 2017 Nov 1;174(11):1064-1074
pubmed: 28774193
J Epidemiol Community Health. 2011 Nov;65(11):958-63
pubmed: 20940172
Psychol Med. 2017 Dec;47(16):2753-2766
pubmed: 28585513
Health Soc Care Community. 2018 Mar;26(2):147-157
pubmed: 27413007
Compr Psychiatry. 2010 Sep-Oct;51(5):471-9
pubmed: 20728003
Am J Psychiatry. 2019 Oct 1;176(10):811-819
pubmed: 31256609
Schizophr Res. 2005 Apr 1;74(1):15-26
pubmed: 15694750
BMJ. 2012 Jan 05;344:d7622
pubmed: 22223828
Harv Rev Psychiatry. 2016 Mar-Apr;24(2):118-28
pubmed: 26954596
Annu Rev Clin Psychol. 2014;10:425-48
pubmed: 24313570
Am J Psychiatry. 2001 Sep;158(9):1441-8
pubmed: 11532729
Schizophr Res. 2006 Jan 1;81(1):17-27
pubmed: 16297601
Am J Psychiatry. 1999 Sep;156(9):1336-41
pubmed: 10484942
Am J Psychiatry. 2000 Sep;157(9):1453-60
pubmed: 10964862
Schizophr Res. 2015 Jun;165(1):76-82
pubmed: 25868935